Achieve Life Sciences Inc (ACHV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.49+2.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACHV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -45.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ACHV — earnings miss
Dated 2026-08-14
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
Why it matters: The trial's progress is key to proving cytisinicline works. Good results may help investors.
Supportive ifThey shared good interim results from the ORCA-V2 Phase 3 trial for cytisinicline.
Worry ifAnnounce negative results or delays in the ORCA-V2 Phase 3 trial.
Why it matters: Better cash flow shows improved efficiency and financial health. It is important for funding projects.
Supportive ifCash flow from operations turns positive in Q2 2026.
Worry ifCash flow from operations remains negative or worsens in Q2 2026.
Why it matters: Bigger losses may show serious financial problems. This can change how investors feel.
Worry ifNet income losses reported above $74.8 million for Q2 2026.
Less concerning ifNet income losses reported below $74.8 million for Q2 2026.
Why it matters: Funding is key for running operations and plans for growth.
Supportive ifThe company announced it finished private placement funding. It raised at least $354 million.
Worry ifNot finishing the private placement or big delays in the process.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$235 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $633 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,455 loss on $10,000 · 54.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This letter will show if cytisinicline can move forward in the approval process. A positive answer is important for the company's future.
Supportive ifThe FDA sends a letter. It approves cytisinicline.
Worry ifThe FDA sends a letter. It denies approval for cytisinicline.
Why it matters: If health care revenue growth speeds up, it may support Achieve's recovery.
Supportive ifHealth care sector revenue growth is speeding up toward 10% or more.
Worry ifRevenue growth keeps slowing down below 10%.
Why it matters: Updates on this trial will show how well cytisinicline helps people stop using e-cigarettes. Good results could increase trust in the drug.
Supportive ifGood interim results were announced from the ORCA-V2 trial.
Worry ifNegative results or delays in trial updates.
Why it matters: Resubmitting the NDA is a key step towards FDA approval. It signals progress in the regulatory process.
Supportive ifThe company announced it will resubmit the NDA. Adare will be the manufacturing partner.
Worry ifNo news or more delays in the NDA resubmission.
Why it matters: The letter will indicate if cytisinicline can move forward in the approval process. This is crucial for the company's future.
Watch forA Complete Response Letter from the FDA that allows resubmission of the NDA.
Also watch forA letter shows more problems that slow down the approval process.
Why it matters: Changes in leadership can change how the company launches cytisinicline. Strong leaders help success.
Watch forThe company announced new commercial leaders. They will work on the launch strategy.
Also watch forNo updates or negative feedback on the new leadership structure.